NCT05517200

Brief Summary

This study is a single center, random participant selection, data analyst is blinded to patient identifiers, controlled clinical trial. The proposed study is intended to establish safety and efficacy of quantifiable electrical biomarkers for migraine that can be used to confirm a diagnosis in people that have already been screened as positive for migraine using the gold standard participative criteria set out in the International Classification of Headache disorders-3 (ICHD-3) criteria. It is hypothesized that specific brain signals can be used to distinguish between migraine patients with and without aura from normal control and tension- type headache control participants by EEG enhanced with machine learning software.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Sep 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 24, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 26, 2022

Completed
8 days until next milestone

Study Start

First participant enrolled

September 3, 2022

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2025

Completed
Last Updated

September 29, 2023

Status Verified

September 1, 2023

Enrollment Period

2.7 years

First QC Date

August 24, 2022

Last Update Submit

September 27, 2023

Conditions

Keywords

EEGMachine LearningMigraineHeadacheDiagnosisArtificial Intelligence

Outcome Measures

Primary Outcomes (1)

  • Feasibility of machine learning as applied to EEG to diagnose migraine.

    The primary endpoint is a sensitivity of 79% and a specificity of 72% in distinguishing migraine with and without aura screened using the ICHD-3 benchmark criteria as compared to normal controls.

    2 years

Study Arms (2)

Normal Control

These participants are normal control in good mental and psychiatric health.

Diagnostic Test: Machine Learning Test for Migraine

Migraine

These participants have migraines according to ICHD-3 criteria.

Diagnostic Test: Machine Learning Test for Migraine

Interventions

Resting EEG, and Visual and Auditory Stimulation

Also known as: MLTM
MigraineNormal Control

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All participants and controls will be adults over 18, and no greater than 70. Migraine patients and controls to reflect the demographics of the disease such that there is a balanced mix of males to females that reflects known female to male ratio for migraine is 3 to 1. They are capable of giving clear and reliable answers on the questionnaires. All potential participants should be able to read, write and speak in English, unless they can bring a translator. All mentally competent to give accurate answers on questionnaires, to decide for themselves and sign the informed consent form. All medically stable patients. Capable of safely using a staircase to our downstairs lab. Normal controls must be very healthy.

You may qualify if:

  • ● Age range: All participants and controls will be adults over 18, and no greater than 70
  • Sex: Migraine patients and controls to reflect the demographics of the disease such that there is a balanced mix of males to females that reflects known female to male ratio for migraine is 3 to 1.
  • Capable of giving clear and reliable answers on the questionnaires
  • All potential participants should be able to read, write and speak in English: unless they can bring a translator.
  • All mentally competent: to give accurate answers on questionnaires, to decide for themselves and sign the informed consent form.
  • All medically stable patients.
  • Capable of safely using a staircase to our downstairs lab
  • OHIP must be up-to-date and participants must show a valid OHIP number
  • Able and willing to comply with all study requirements
  • Normal controls must be very healthy.

You may not qualify if:

  • ● Under 18 years old
  • Over 70 years old (71 and above)
  • Incompetent in english language and no translator (This applies to reading, writing and speaking.)
  • Current moderate or serious mental illness (including depression, anxiety disorder, psychosis)
  • Mentally disabled/ Mentally incompetentHistory of photo-epilepsy or history of seizure following shortly after visual stimulus such as bright or repetitive flashes of light, repetitive flashes of light (such as at a disco, or looking at an overhead fan), or after looking at repetitive visual patterns lines such as looking at multiple stripes or squares, or from seeing movement such as when watching an action movie.
  • Medically unstable
  • Prisoner
  • Unable to go down the stairs (if recording is downstairs)
  • Pacemaker
  • Defibrillator
  • Cochlear implants
  • Significant skull deformity (e.g. a depression of greater than half an inch
  • Head injury with consciousness loss in the last year, even with apparent full recovery.
  • Severe facial trauma within the last three months, or longer if unrecovered.
  • Unnatural material inside the head or mouth based on history (including clips from surgery, shrapnel, bullet, medical pump, wires, medical device, metal dental implants)
  • +13 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Headache Sciences Incorporated Laboratory

Toronto, Ontario, M4M1G9, Canada

RECRUITING

Related Links

MeSH Terms

Conditions

Migraine DisordersTension-Type HeadacheHeadacheDisease

Condition Hierarchy (Ancestors)

Headache Disorders, PrimaryHeadache DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsPathologic Processes

Central Study Contacts

Mark S. Doidge, MD, BA

CONTACT

Gaurav Anand, MD, BSc

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Target Duration
1 Day
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 24, 2022

First Posted

August 26, 2022

Study Start

September 3, 2022

Primary Completion

June 1, 2025

Study Completion

June 1, 2025

Last Updated

September 29, 2023

Record last verified: 2023-09

Data Sharing

IPD Sharing
Will not share

Locations